CURE Pharmaceutical to Acquire Sera Labs for $20 Million

Item 9 Labs Corp. Acquires The Herbal Cure (Denver)

March 17, 2022

Retail

Item 9 Labs Corp. (OTCQX: INLB) signed an Asset Purchase Agreement to acquire The Herbal Cure, a Denver-based medicinal and recreational cannabis dispensary and cultivator. The acquisition — which includes a 5,000 sq ft facility with 3,500 sq ft of retail/corporate space and a separate 3,000 sq ft cultivation area — will be converted to Item 9’s Unity Rd. dispensary brand pending regulatory approvals; The Herbal Cure reported $5.4 million in 2021 revenue.

Curative Inc. Acquires KorvaLabs, Inc.

May 19, 2020

Healthcare Services

Curative Inc. has acquired KorvaLabs, a CLIA-certified and DEA-licensed analytical laboratory based in San Dimas, California, formalizing a partnership that supported Curative's manufacture and processing of its oral fluid COVID-19 test. The acquisition strengthens Curative's testing capacity — to date the organizations processed 245,371 tests together and were processing roughly 14,000 tests per day — and secures in-house manufacturing and processing capabilities.

SERB Pharmaceuticals Acquires Y-mAbs Therapeutics

September 16, 2025

Biotechnology

SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.

Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific

December 1, 2020

Pharmaceuticals

Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

Curaleaf Acquires Deseret Wellness

March 29, 2023

Retail

Curaleaf Holdings, Inc. agreed to acquire Deseret Wellness in a cash-and-stock transaction valued at approximately US$20 million. The deal adds three medical cannabis dispensaries in Park City, Provo and Payson (combined annualized revenue ~$14 million), expanding Curaleaf’s Utah retail footprint to four dispensaries and its nationwide store count to about 150.